CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM

RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were met and there was no survival benefit from adding d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew, Stern, Yaakov, Wang, Tony, Aldape, Kenneth, Armstrong, Terri, Vogelbaum, Michael, Sulman, Erik, Moazami, Golnaz, Macsai, Marian, Gilbert, Mark, Bain, Earle, Blot, Vincent, Gan, Hui, Preusser, Matthias, Ansell, Peter, Samanta, Suvajit, Kundu, Madan, Seidel, Clemens, de Vos, Filip, Hsu, Sigmund, Cardona, Andres, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard, Gedye, Craig, Lebrun-Frenay, Christine, Wick, Antje, Pugh, Stephanie, Curran, Walter, Mehta, Minesh
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Clinical Trials: Non-Immunologic
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650869/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.217
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge